SPP1 and neoplasm: By inhibiting key signaling molecules such as SPP1 and CXCL12 or even by interfering with exosome release, researchers hope to disrupt the paracrine communication that fosters antiangiogenic TKI resistance and promotes tumor survival [32,62,63,64,65].